Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03320824
Other study ID # 43USK1701
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 13, 2017
Est. completion date April 23, 2019

Study information

Verified date June 2020
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To demonstrate non-inferiority of Kysse versus a control in lip fullness augmentation


Recruitment information / eligibility

Status Completed
Enrollment 273
Est. completion date April 23, 2019
Est. primary completion date June 28, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: - Subjects willing to comply with the requirements of the study and providing a signed written informed consent. - Males or non-pregnant, non-breastfeeding females, 22 years of age or older. - Seeking augmentation therapy for the lips Exclusion Criteria: - Allergy of hypersensitivity to any injectable hyaluronic acid gel or to gram positive bacterial proteins. - Allergy or hypersensitivity to lidocaine or other amide-type anesthetics, or topical anesthetics or nerve blocking agents.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
New Dermal Filler
hyaluronic acid
Device: FDA Approved Dermal Filler
hyaluronic acid

Locations

Country Name City State
United States Atlanta Dermatology, Vein & Research Center, LLC Alpharetta Georgia
United States BOYD Birmingham Michigan
United States Aesthetic Solutions, PA Chapel Hill North Carolina
United States SkinCare Physicians Chestnut Hill Massachusetts
United States Skin Research Institute, LLC Coral Gables Florida
United States Center for Advanced Clinical Research Dallas Texas
United States Clinical Testing of Bevelry Hills Encino California
United States Maryland Dermatology, Laser, Skin & Vein Institute Hunt Valley Maryland
United States University of Miami Miami Florida
United States Brian S. Biesman, MD Nashville Tennessee
United States Laser & Skin Surgery Center of New York New York New York
United States Cosmetic Laser Dermatology San Diego California
United States Art of Skin MD Solana Beach California
United States Research Institute of SouthEast West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluate All Reported Adverse Events 48 weeks
Primary Assess Effectiveness of the Treatment Using the Medicis Lip Fullness Scale (MLFS) The MLFS is a validated photograph-based outcome instrument that is designed specifically for quantifying lip fullness. Scoring of lip fullness (grades 0-5, with a higher score reflecting greater lip fullness) was based on visual live assessment by the Blinded Evaluator at defined time points, and not on a comparison to the baseline appearance. Effectiveness is defined as change from baseline at 8 weeks after last injection of New Dermal Filler or Dermal Filler (control). 8 weeks after last injection
Secondary Assess Effectiveness of the New Dermal Filler Treatment in the Upper & Lower Lips Using the Medicis Lip Fullness Scale The MLFS is a validated photograph-based outcome instrument that is designed specifically for quantifying lip fullness. Scoring of lip fullness (grades 0-5, with a higher score reflecting greater lip fullness) was based on visual live assessment by the Blinded Evaluator at defined time points, and not on a comparison to the baseline appearance. Effectiveness is defined as change from baseline at X weeks after last injection of New Dermal Filler. 16, 24, 32, 40, and 48 weeks after last injection
Secondary Assess Effectiveness of the New Dermal Filler Treatment in the Upper & Lower Lips Using the Medicis Lip Fullness Scale Based on Response Rates (defined as at least 1 point improvement from baseline) after treatment with New Dermal Filler 16, 24, 32, 40, and 48 weeks
Secondary Assess Aesthetic Improvement in the Perioral Rhytids & Oral Commissures After New Dermal Filler Treatment Using the Wrinkle Assessment Scale (Change From Baseline, Blinded Evaluator) Based on Change from Baseline, New Dermal Filler using WAS. Scoring of the upper perioral rhytids and oral commissures was based on visual live assessment by the Blinded Evaluator at defined time points, and not on a comparison to the baseline appearance. Scoring of fold severity was based on visual assessment of the length and apparent depth of the wrinkle at a certain time-point and measured on a 6-point scale, with 0 being no wrinkle and 5 being very deep wrinkle/redundant fold. 8, 16, 24, 32, 40, and 48 weeks after last injection
Secondary Assess Aesthetic Improvement in the Perioral Rhytids & Oral Commissures After New Dermal Filler Treatment Using the Wrinkle Assessment Scale (Response Rates, Blinded Evaluator) Based on Response Rates (defined as at least 1 point improvement from baseline), New Dermal Filler using WAS. Scoring of the upper perioral rhytids and oral commissures was based on visual live assessment by the Blinded Evaluator at defined time points, and not on a comparison to the baseline appearance. Scoring of fold severity was based on visual assessment of the length and apparent depth of the wrinkle at a certain time-point and measured on a 6-point scale, with 0 being no wrinkle and 5 being very deep wrinkle/redundant fold. . 8, 16, 24, 32, 40, and 48 weeks
Secondary Assess Overall Aesthetic Improvement After New Dermal Filler Treatment Using the Global Aesthetic Improvement Scale Determined by Response Rates, Subject Assessment Responders defined as at least "improved" (improved, much improved, very much improved) as assessed by subject, upper and lower lip combined, New Dermal Filler 8, 16, 24, 32, 40, and 48 weeks
Secondary Assess Overall Aesthetic Improvement After New Dermal Filler Treatment Using the Global Aesthetic Improvement Scale, Treating Investigator Determined by Response Rates, Treating Investigator Assessment, New Dermal Filler 8, 16, 24, 32, 40, and 48 weeks
Secondary Assessment of Improvement in Lip Fullness After New Dermal Filler Treatment, by Independent Photographic Reviewer Proportion of Improvement (Responders) Based on Independent Photographic Reviewer Assessment by Weeks after Last Injection, New Dermal Filler 8, 24, 40, and 48 weeks
Secondary Assess Subject Satisfaction With New Dermal Filler Treatment Using the FACE-Q Subjects' satisfaction using the validated FACE-Q scales Satisfaction with Lips and Appraisal of Lines: Lips at baseline and at Week 8, 16, 24, 32, 40, and 48 weeks after last injection based on individual questions in each questionnaire as well as the Rasch transformed total scores and the change from baseline in the Rasch transformed scores. Rasch-transformed total score (0-100) according the FACE-Q manual; the higher total score indicated greater subject satisfaction.A positive change from baseline indicates an improvement. Baseline is defined as the last observation before initial treatment takes place at the baseline visit on Day 1. 8, 16, 24, 32, 40, and 48 weeks
See also
  Status Clinical Trial Phase
Completed NCT04540913 - RHA® 3 Versus Restylane-L® for Lip Augmentation
Completed NCT05730543 - Ethnic Lip Augmentation With Hyaluronic Acid Filler Phase 3
Completed NCT04839692 - Assessment and Augmentation of Lip Appearance in Specific Study Populations Phase 4
Completed NCT03967444 - Study to Evaluate Satisfaction After Treatment With Kysse N/A
Terminated NCT04299295 - To Evaluate the Performance and Safety of YVOIRE Y Solution 360 Versus Comparator for Lips and Perioral Area. N/A
Completed NCT01629134 - Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the Lips N/A
Terminated NCT04029545 - A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation Phase 3
Active, not recruiting NCT05342753 - Safety and Effectiveness of Restylane® Kysse for Lip Augmentation in Chinese Subjects N/A
Completed NCT00935272 - Safety/Efficacy Study of Restylane® in Lip Augmentation N/A
Recruiting NCT05314504 - Clinical Investigation of YVOIRE Y-Solution 360 for Lip Augmentation in China N/A
Completed NCT04029519 - A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation Phase 3
Completed NCT03796728 - A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation Phase 4
Completed NCT01197495 - Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation N/A